Myocardial ischemia is caused by the incoordination between myocardial oxygen consumption and oxygen delivery in coronary artery disease, and due to its high morbidity and mortality rate, the number of patients who die from ischemic heart disease in China is increasing year by year. In order to verify that the active ingredients of Jinlume have anti-myocardial ischemic efficacy. The maximum tolerated concentration (MTC) was determined to be 15.63 μg/mL by the pre-test, and the high school and low dose groups were divided into 7.81 μg/mL (1/2 MTC), 2.60 μg/mL (1/6 MTC) based on the MTC, respectively, 0.868 μg/mL (1/18 MTC), and the positive drug group was N-acetylcysteine (125 μg/mL). With the help of network pharmacology and molecular docking technology, the possible mechanism of action of the active ingredients of Jinlume in inhibiting cardiomyocyte apoptosis and slowing down myocardial ischemia was investigated. The results showed that the aqueous extract of Jinlume had significant effects against myocardial ischemia in comparison with the positive drug group by means of zebrafish cardiac fluorescence intensity phenotyping, and its mechanism of action was related to five pathways, namely, Rap1 signaling pathway, cancer pathway, proteoglycans in cancer, PI3K-Akt signaling pathway, lipids, and atherosclerosis. It can be seen that exploring the anti-myocardial ischemic mechanism of the active ingredients of Jinlume has certain theoretical significance for the prevention and treatment of myocardial ischemia.